Table 6.
Clinical relevance of cardiovascular and circulatory cells in patients with COVID-19 and potential underlying mechanisms leading to cardiovascular disease.
Contributing cells | Clinical relevance | Potential underlying mechanisms leading to CVD |
---|---|---|
Cardiovascular cells | Cardiovascular cell-related mechanisms: | |
Cardiomyocytes1 | Wide expression of ACE2 | SARS-CoV-2 uses ACE2 as a cell receptor → direct myocardial damage |
Cardiac pericytes2 | High ACE2 expression | SARS-CoV-2 uses ACE2 as a cell receptor → pericyte is a potential host cell targeted by SARS-CoV-2 in cardiac tissue capillary → capillary endothelial cells dysfunction → coronary microvascular dysfunction |
Endothelial cells3, 4, 5 | Evidence of direct SARS-CoV-2 infection of the endothelial cells and diffuse endothelial inflammation | Increased ACE2 expression by endothelial cells and evidence of direct viral infection of vascular organoids in vitro → endothelial inflammation (“endotheliitis”) and increased leukocyte infiltration in heart tissue → atherosclerotic plaque destabilization → acute coronary syndrome |
Blood cells | Leukocyte-related mechanisms: | |
Lymphocytes6, 7, 8, 9, 10 | ↓ in all cases, especially in severe disease |
|
CD4+ T cells11, 12, 13, 14 | ↓ in severe disease ✓Autopsy-confirmed CD4+ T infiltration of myocardium |
|
CD8+ T cells15,16 | ↓ in severe disease |
|
NK cells14,15 | ↓ in all cases |
|
Neutrophils17, 18, 19 | ↑ in severe disease |
Platelet-related mechanism: Platelets become activated → platelets adhere to vascular endothelium promoting further recruitment of leukocytes to vascular wall → vascular inflammation and tissue inflammation → inflammatory cardiomyopathy, atherothrombosis, and vasculitis |
Platelets177,178 | ↓ in severe disease |
ACE2: angiotensin-converting enzyme 2, COVID-19: coronavirus disease 2019, CV: cardiovascular.
CVD: cardiovascular disease, NK: natural killer, and SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.